United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid injection is indicated for treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget's disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5) ]. zoledronic acid injection is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.2) ] - creatinine clearance less than 35 ml/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see warnings and precautions (5.3) ]. - known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see adverse reactions (6.2) ]. pregnancy category d [see warnings and precautions (5.6)

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fusidic acid 20.35 mg/g (as the 0.5 hydrate) - topical cream - 20 mg/g - active: fusidic acid 20.35 mg/g (as the 0.5 hydrate) excipient: butylated hydroxyanisole cetyl alcohol glycerol hydrochloric acid liquid paraffin polysorbate 60 potassium sorbate purified water white soft paraffin - indicated either alone or in combination with systemic therapy, in the treatment of primary and secondary skin infections caused by sensitive strains of staphylococcus aureus, streptococcus spp and corynebacterium minutissimum. primary skin infections that may be expected to respond to treatment with fusidic acid applied topically include: impetigo contagiosa, superficial folliculitis, sycosis barbae, paronychia and erythrasma; also such secondary skin infections as infected eczematoid dermatitis, infected contact dermatitis and infected cuts/abrasions.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid 5 mg in 1 ml - folic acid injection, usp alone is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid as may be seen in tropical or nontropical sprue, in anemias of nutritional origin, pregnancy, infancy or childhood.

Canada - English - Health Canada

boiron laboratoires - hydrochloric acid - drops - 2ch - hydrochloric acid 2ch - homeopathic products

Canada - English - Health Canada

boiron laboratoires - hydrochloric acid - tablet - 2ch - hydrochloric acid 2ch - homeopathic products

Canada - English - Health Canada

homeocan inc. - hydrochloric acid - tablet - 1dh - hydrochloric acid 1dh - homeopathic products

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - tranexamic acid, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - intravenous administration,adults,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

United States - English - NLM (National Library of Medicine)

morton grove pharmaceuticals, inc. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who a

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

contact organics pty ltd - hydrochloric acid; acetic acid - soluble concentrate - hydrochloric acid acid active 10.0 g/l; acetic acid acid-general active 900.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: egg lecithin; glycerol; sodium oleate; water for injections; sodium hydroxide; dl-alpha-tocopherol - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.